1 / 15

Hepatitis B

Hepatitis B. Epidemiology. HBV infection acquired early in life is a major cause of chronic liver disease, including cirrhosis, and primary liver cancer The hepatitis B virus is the 2 nd most important known human carcinogen, after tobacco

mizell
Télécharger la présentation

Hepatitis B

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatitis B

  2. Epidemiology • HBV infection acquired early in life is a major cause of chronic liver disease, including cirrhosis, and primary liver cancer • The hepatitis B virus is the 2nd most important known human carcinogen, after tobacco • Up to 400 million people, mostly in the Asia Pacific region, are chronically HBV– infected

  3. Australia • There is currently an epidemic of chronic Hepatitis B in Australia • In Australia up to 160,000 are chronically infected with HBV – half are from endemic countries of the Asia Pacific region • Unlike HIV and Hep C (sexy infections) there is no comprehensive national Hepatitis B public health strategy • Universal hepatitis B vaccination for infants and people at high risk of infection has been implemented in Australia since 2000

  4. Australia

  5. At Risk Groups in Australia • IV drug users (16% of prevalence but 40% of all new acute cases. Usually co-infected with hepatitis C increasing risk of chronic illness and advanced liver disease) • People born in an endemic region • Asia and the Pacific Islands (50% of prevalence) • Africa, the Middle East, and the Mediterranean region • Homosexual men (8%) • Indigenous - the virus was discovered in 1965 in Australian aborigines. They make up 2% of the total population but 16% of the total prevalence of chronic hepatitis B. • Prisoners

  6. At Risk Groups in Australia

  7. Transmission of HBV • Saliva, semen, blood • Perinatal – risk of disease is 80% from mother +ve to HBsAg and HNeAg • To children through household contact • In healthcare settings and sharing of contaminated equipment

  8. Age Determimes Course of Illness

  9. Virology • Hep B is a DNA virus and uses reverse transcription to copy its DNA • The virus does not kill cells but expression of antigens causes both cytotoxic CD8+ T cell lysis (minor defence) and secretion of cytokines (IFN-γ and TNF-α ) causing non-cytolytic viral inhibition (major defence) see http://www.jimmunol.org/content/184/1/287 • The antigens expressed by infected hepatocytes are: • Surface antigen • Core antigen • E antigen (a soluble protein secreted by the virus into the bloodstream)

  10. Acute HBV Infection - Clinical • Symptoms: primarily jaundice after 8 weeks (range 6-12 weeks) but other symptoms can appear such as malaise, nausea, vomiting, LOA, arthralgia, myalgia • Serological markers • HBV DNA early marker (2 weeks after infection) • HBs-Ag can be detected 1 month after infection • anti-HBc IgM and Hbe-Ag at 8 weeks • LFT’s: ALT, AST • Mortality is 1%

  11. Chronic HBV Infection - Clinical • Defined clinically by serological markers: HBs-Ag persisting for longer than 6 months • Other markers are usually variable

  12. Phases of Chronic HBV Infection • Immune tolerant phase: the immune system doesn’t recognise surface or e antigens and a high viral load (high HBV DNA) persisting for 20-30 years if infected perinatally or during childhood • HBeAg clearance phase: development of anti-Hbe (Hbe-Ag seroconversion) and development of immune response causing: • Liver inflammation, raised LFT’s • Flare-ups causing jaundice • Progression of liver disease to possible advanced liver disease if high viral load HBV DNA > 100,000 IU/mL • Low/non replicative phase: almost complete eradication of the virus with normal LFT’s and low HBV DNA, minimal liver damage and low risk of developing advanced live disease • Reactivating phase: immunosuppression typically is the cause of reactivation of the infection, inflammation and raised ALT/AST with increasing HBV DNA but no return of Hbe-Ag. Advance liver disease can develop if HBV DNA is > 100,000 IU/mL

  13. Treatment of Hep B • The targets of treatment are: • Inhibit viral DNA replication • Enhance the immune response (as already mentioned, the main immune response is the non-cytolytic one involving cytokines)

  14. Ongoing Treatment • Medicare only pays for monotherapy, which is suboptimal - cf successful combination therapies subsidised for “sexier” Hep C and HIV • Nucleoside monotherapy has been associated with development of resistance • LFT’s and serology are performed every 3 months to determine effectiveness of treatment (not covered by Medicare)

More Related